T. Rowe Price Associates’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $743K | Sell |
927,608
-48,539
| -5% | -$38.9K | ﹤0.01% | 2115 |
|
|
2025
Q1 | $750K | Sell |
976,147
-53,052
| -5% | -$40.8K | ﹤0.01% | 2085 |
|
|
2024
Q4 | $1.31M | Sell |
1,029,199
-68,400
| -6% | -$86.9K | ﹤0.01% | 1846 |
|
|
2024
Q3 | $2.27M | Buy |
1,097,599
+206,301
| +23% | +$427K | ﹤0.01% | 1572 |
|
|
2024
Q2 | $3.4M | Sell |
891,298
-50,673
| -5% | -$193K | ﹤0.01% | 1356 |
|
|
2024
Q1 | $4.47M | Sell |
941,971
-100,766
| -10% | -$478K | ﹤0.01% | 1245 |
|
|
2023
Q4 | $4.45M | Sell |
1,042,737
-24,121
| -2% | -$103K | ﹤0.01% | 1235 |
|
|
2023
Q3 | $3.3M | Sell |
1,066,858
-15,390
| -1% | -$47.6K | ﹤0.01% | 1294 |
|
|
2023
Q2 | $4.87M | Buy |
1,082,248
+797,886
| +281% | +$3.59M | ﹤0.01% | 1191 |
|
|
2023
Q1 | $1.62M | Sell |
284,362
-16,315
| -5% | -$93.1K | ﹤0.01% | 1546 |
|
|
2022
Q4 | $1.82M | Sell |
300,677
-12,488
| -4% | -$75.4K | ﹤0.01% | 1506 |
|
|
2022
Q3 | $2.07M | Buy |
313,165
+5,812
| +2% | +$38.4K | ﹤0.01% | 1439 |
|
|
2022
Q2 | $1.6M | Sell |
307,353
-15,635
| -5% | -$81.6K | ﹤0.01% | 1692 |
|
|
2022
Q1 | $2.23M | Buy |
322,988
+18,656
| +6% | +$129K | ﹤0.01% | 1650 |
|
|
2021
Q4 | $3.79M | Sell |
304,332
-90,944
| -23% | -$1.13M | ﹤0.01% | 1540 |
|
|
2021
Q3 | $12.4M | Sell |
395,276
-5,526
| -1% | -$173K | ﹤0.01% | 1401 |
|
|
2021
Q2 | $11.5M | Sell |
400,802
-22,189
| -5% | -$635K | ﹤0.01% | 1400 |
|
|
2021
Q1 | $18.3M | Buy |
422,991
+35,311
| +9% | +$1.53M | ﹤0.01% | 1292 |
|
|
2020
Q4 | $27.7M | Sell |
387,680
-12,320
| -3% | -$882K | ﹤0.01% | 1130 |
|
|
2020
Q3 | $12.1M | Buy |
+400,000
| New | +$12.1M | ﹤0.01% | 1256 |
|